Syndax Pharmaceuticals Future Growth
Future criteria checks 2/6
Syndax Pharmaceuticals is forecast to grow earnings and revenue by 19.4% and 45.9% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be -52.4% in 3 years.
Key information
19.4%
Earnings growth rate
25.7%
EPS growth rate
Biotechs earnings growth | 24.7% |
Revenue growth rate | 45.9% |
Future return on equity | -52.4% |
Analyst coverage | Good |
Last updated | 27 Apr 2024 |
Recent future growth updates
Recent updates
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Is Syndax Pharmaceuticals (NASDAQ:SNDX) Weighed On By Its Debt Load?
Jun 11Shareholders Would Not Be Objecting To Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Compensation And Here's Why
May 07The Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Has Gained 150%, So Why Not Pay It Some Attention?
Mar 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 227 | -204 | -95 | -155 | 8 |
12/31/2025 | 116 | -256 | -173 | -241 | 12 |
12/31/2024 | 29 | -314 | -257 | -278 | 12 |
12/31/2023 | N/A | -209 | -161 | -161 | N/A |
9/30/2023 | N/A | -176 | -142 | -142 | N/A |
6/30/2023 | N/A | -160 | -126 | -126 | N/A |
3/31/2023 | N/A | -153 | -131 | -131 | N/A |
12/31/2022 | N/A | -149 | -134 | -134 | N/A |
9/30/2022 | 127 | -14 | -10 | -10 | N/A |
6/30/2022 | 139 | 1 | -7 | -6 | N/A |
3/31/2022 | 139 | 15 | 10 | 10 | N/A |
12/31/2021 | 140 | 25 | 29 | 29 | N/A |
9/30/2021 | 14 | -92 | -87 | -87 | N/A |
6/30/2021 | 2 | -91 | -81 | -81 | N/A |
3/31/2021 | 2 | -86 | -78 | -78 | N/A |
12/31/2020 | 2 | -77 | -71 | -71 | N/A |
9/30/2020 | 2 | -71 | -68 | -68 | N/A |
6/30/2020 | 2 | -63 | -59 | -59 | N/A |
3/31/2020 | 2 | -61 | -50 | -50 | N/A |
12/31/2019 | 2 | -56 | -51 | -51 | N/A |
9/30/2019 | 2 | -61 | -53 | -53 | N/A |
6/30/2019 | 2 | -65 | -63 | -63 | N/A |
3/31/2019 | 2 | -69 | -66 | -65 | N/A |
12/31/2018 | 2 | -74 | -69 | -69 | N/A |
9/30/2018 | 2 | -74 | -66 | -66 | N/A |
6/30/2018 | 2 | -72 | -58 | -58 | N/A |
3/31/2018 | 2 | -67 | -55 | -55 | N/A |
12/31/2017 | 2 | -61 | -47 | -47 | N/A |
9/30/2017 | 1 | -53 | N/A | -45 | N/A |
6/30/2017 | 1 | -52 | N/A | -46 | N/A |
3/31/2017 | 1 | -47 | N/A | -41 | N/A |
12/31/2016 | 1 | -47 | N/A | -35 | N/A |
9/30/2016 | 1 | -45 | N/A | -29 | N/A |
6/30/2016 | 1 | -87 | N/A | -23 | N/A |
3/31/2016 | 1 | -105 | N/A | -20 | N/A |
12/31/2015 | 1 | -104 | N/A | -2 | N/A |
9/30/2015 | 0 | -100 | N/A | -2 | N/A |
6/30/2015 | 0 | -53 | N/A | 1 | N/A |
3/31/2015 | N/A | -33 | N/A | 1 | N/A |
12/31/2014 | N/A | -26 | N/A | -14 | N/A |
9/30/2014 | N/A | -31 | N/A | -14 | N/A |
6/30/2014 | N/A | -72 | N/A | -13 | N/A |
3/31/2014 | N/A | -67 | N/A | -10 | N/A |
12/31/2013 | N/A | -60 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SNDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SNDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SNDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SNDX's revenue (45.9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: SNDX's revenue (45.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SNDX is forecast to be unprofitable in 3 years.